Clinical Trial Search

Primary: Mean Self-reported Adherence Score (%) Over a One-month Recall — 97.5; 98.2 percentage of adherence score — p=0.52

Primary: Change in Tenofovir Diphosphate (TFV-DP) Drug Levels — 1230; 1108; 1887; 1084 fmol/punch — p=0.070

Primary: Number of Participants Who Reported Experiences With the ARICA Program — 12 Participants

Primary: Intervention Feasibility as Measured by Number of Providers Agreeing to Participate — 6 Participants

Primary: Medication Adherence — 88.1; 96.6; 94.4 percentage of doses taken (pill count)

Primary: Rate of Medication Adherence — 0.76; 0.79; 0.83 percentage of doses taken — p=0.78

Primary: Blood Pressure Medication Adherence — 396; 470 Participants — p=0.0103

Primary: Percent of Participants With Adherence at Month 6 — 91; 40 percent persistent on therapy — p=<0.05

Primary: Adherence Measured by Sensor by Percentage of Prescribed Medications Taken — 87.5 percentage of prescribed medication

Primary: Adherence to Statins — 0.55; 0.57; 0.58; 0.38 mMPR as a fraction — p=<.001

Primary: Feasibility of Retaining Study Participants Through the 3 Month Trial — 20; 21 Participants

Primary: Mean Adherence, as Measured by Electronic Drug Monitors (EDM) — 96.5; 84.5; 96.4; 84.1 percentage of doses taken on time

Primary: Change in Self Reported Medication Adherence — 0.78; 0.74; 0.53; 0.62 Scores on a scale — p=0.22

Primary: AIDS Clinical Trials Group (ACTG) 3-day Recall Measure of Doses Taken — 72.89; 75.46; 74.86; 77.33 percent with 100% adherence — p=0.12

Primary: Percentage of Adherent Participants — 65; 38 percentage of participants — p==0.004

Primary: Percentage of Visits With Appropriate Hypertension Management — 34; 69 percentage of patient-clinician visits — p=<=0.001

Primary: Antiretroviral Therapy (ART) Adherence (Self-reported 3-day Recall Measure) — 142; 139; 6; 12 participants

Primary: Percentage of Participants With Plasma Human Immunodeficiency Virus - Type I Ribonucleic Acid (HIV-1 RNA) Levels Less Than (<) 50 Copies/mL at Week 12 — 24.4; 20.9…

Primary: Statin Adherence — 86; 85; 86; 85 percentage of correct statin doses

Primary: Depression From (1) Clinician-Administered MADRS Measure, and (2) Participant Self-Report Ratings With BDI-1a — 17.8; 19.2; 19.7; 17.7 Units on a scale

Primary: Change From Baseline in the Tablet Routine Questionaire (TRQ) "Past Month" Item at 24 Weeks — 21.5; 28.0 percent of medications not taken

Primary: Number of Participants in Each Condition With Optimal ART Adherence — 27; 29 participants

Primary: Antipsychotic Medication Adherence — 63.9; 75.0 percentage of participants — p=0.03

Primary: Medication Adherence — 21.6; 23.8 score on a scale

Primary: Generalized Anxiety Disorder-7 (Gad-7) — 14.86; 12.88; 8.33; 7.62 units on a scale

Primary: Median Proportion of Days Covered (PDC) at 8-months Post-enrollment — 0.94; 0.88 proportion of days covered (PDC) — p=0.001

Primary: Rate of Medication Adherence — 2; 1 Participants

Primary: Statin Adherence — 79; 84; 80 percentage of correct statin doses

Primary: Feasibility of the Intervention - Number of Counseling Sessions — 2.92; 1 sessions

Primary: Adherence to Antiretroviral Therapy Per Self-Report — 85.3; 79.0; 92.8; 77.8 percentage of self-reported adherence — p=0.11